RO5045337

DRUG6 trials

Sponsors

Hoffmann-La Roche

Conditions

Hematologic NeoplasmsMyelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, AcuteNeoplasmsSarcoma

Phase 1

A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors

CompletedNCT00559533

Hoffmann-La RocheNeoplasms

Start: 2007-12-31End: 2012-11-30Updated: 2016-11-02

A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

CompletedNCT00623870

Hoffmann-La RocheHematologic Neoplasms

Start: 2008-05-31End: 2012-11-30Updated: 2016-11-02

A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery

CompletedNCT01143740

Hoffmann-La RocheSarcoma

Start: 2010-06-30End: 2011-03-31Updated: 2016-11-02

A Study of RO5045337 in Patients With Solid Tumors

CompletedNCT01164033

Hoffmann-La RocheNeoplasms

Start: 2010-08-31End: 2013-05-31Updated: 2016-11-02

A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma

CompletedNCT01605526

Hoffmann-La RocheSarcoma

Start: 2012-05-31End: 2013-06-30Updated: 2016-11-02

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

CompletedNCT01677780

Hoffmann-La RocheMyelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute

Start: 2012-11-28End: 2017-06-26Updated: 2017-07-07